Table 1.
Clinical variables of enrolled subjects with acute liver injury
| Admission variables | Overall population (N=386) |
|---|---|
| Age (years) | 38.0 (28.0–49.0) |
| Gender | |
| Male | 151 (39%) |
| Female | 235 (61%) |
| Race | |
| Caucasian | 276 (72%) |
| African American | 70 (18%) |
| Other | 40 (10%) |
| Etiology of ALIa | |
| APAP toxicity | 194 (50%) |
| Autoimmune hepatitis | 46 (12%) |
| Indeterminate | 42 (11%) |
| Hepatitis A | 25 (6%) |
| Drug-induced liver injury | 23 (6%) |
| Ischemia | 12 (3%) |
| Other | 31 (8%) |
| Duration of symptoms (days) | 5.0 (2.0–14.0) |
| Duration of jaundice (days) | 4.0 (1.0–10.0) |
| Bilirubin (mg/dl) | 5.1 (2.6–15.6) |
| Creatinine (mg/dl) | 0.9 (0.6–1.4) |
| AST (U/l) | 2,269.5 (929.0–5,219.0) |
| ALT (U/l) | 2,784.0 (942.0–5,713.0) |
| Alkaline Phosphatase (IU/ml) | 117.0 (87.0–161.5) |
| Albumin (mg/dl) | 2.9 (2.5–3.2) |
| INR | 2.4 (2.1–3.4) |
| Phosphate (mmol/l) | 2.7 (1.9–3.6) |
| Venous ammonia (µmol/dl) | 65.5 (41.0–94.0) |
ALI, acute liver injury; ALT, alanine aminotransferase; APAP, N-acetyl-p-amino-phenol; AST, aspartate aminotransferase; INR, International normalized ratio.
a
Etiology not recorded for 13 subjects.